Bone Biologics Corporation (BBLG)
Largest Insider Buys in Sector
BBLG Stock Price History Chart
BBLG Stock Performance
About Bone Biologics Corporation
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the …
Insider Activity of Bone Biologics Corporation
Over the last 12 months, insiders at Bone Biologics Corporation have bought $0 and sold $0 worth of Bone Biologics Corporation stock.
On average, over the past 5 years, insiders at Bone Biologics Corporation have bought $205,819 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,000 shares for transaction amount of $5,120 was made by Walsh Deina H (Chief Financial Officer) on 2023‑09‑13.
List of Insider Buy and Sell Transactions, Bone Biologics Corporation
| 2023-09-13 | Chief Financial Officer | 8,000 0.2552% | $0.64 | $5,120 | -55.66% | |||
| 2023-09-11 | Chief Executive Officer | 9,500 0.311% | $0.69 | $6,530 | -55.50% | |||
| 2023-09-06 | Chief Financial Officer | 7,000 0.219% | $0.71 | $4,967 | -58.20% | |||
| 2023-08-31 | Chief Executive Officer | 7,600 0.2366% | $0.66 | $5,020 | -54.06% | |||
| 2020-01-02 | Chairman of the Board | 195,000 1.6745% | $1.00 | $195,000 | +238663.11% | |||
| 2020-01-02 | director | 195,000 1.6745% | $1.00 | $195,000 | +238663.11% | |||
| 2019-08-06 | Chairman of the Board | 553,191 – | $0 | $0 | ||||
| 2019-08-06 | director | 553,191 – | $0 | $0 | ||||
| 2019-07-15 | Chairman of the Board | 85,106 – | $0 | $0 | ||||
| 2019-07-15 | director | 85,106 – | $0 | $0 | ||||
| 2019-06-20 | director | 1.06M – | $0 | $0 | ||||
| 2019-06-20 | Chairman of the Board | 1.06M – | $0 | $0 | ||||
| 2019-05-07 | Chairman of the Board | 1.06M – | $0 | $0 | ||||
| 2019-05-07 | director | 1.06M – | $0 | $0 | ||||
| 2019-03-25 | Chairman of the Board | 1.49M – | $0 | $0 | ||||
| 2019-03-25 | director | 1.49M – | $0 | $0 | ||||
| 2018-12-17 | Chairman of the Board | 18.01M – | $0 | $0 | ||||
| 2018-12-17 | director | 18.01M – | $0 | $0 | ||||
| 2016-02-29 | 10 percent owner | 731,707 23.9735% | $2.05 | $1.5M | ||||
| 2015-12-22 | Sale | director | 5,274 0.1332% | $1.58 | $8,333 |
Insider Historical Profitability
| Hankey Don | Chairman of the Board | 28563398 1159.4486% | $0.90 | 7 | 0 | |
| Hankey Bret | director | 28122518 1141.5523% | $0.90 | 7 | 0 | |
| MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC. | 10 percent owner | 11640096 472.4961% | $0.90 | 1 | 1 | |
| Frelick Jeff | Chief Executive Officer | 17204 0.6983% | $0.90 | 2 | 0 | <0.0001% |
| Walsh Deina H | Chief Financial Officer | 15000 0.6089% | $0.90 | 2 | 0 | <0.0001% |